Literature DB >> 19284033

Field trial for assessment of avian influenza vaccination effectiveness in Indonesia.

A Bouma1, A Teguh Muljono, A Jatikusumah, A J Nell, S Mudjiartiningsih, I Dharmayanti, E Sawitri Siregar, I Claassen, G Koch, J A Stegeman.   

Abstract

The aim of this field study was to determine the efficacy of vaccination against highly pathogenic avian influenza (HPAI) virus strain H5N1 in Indonesia. A limited, prototype clinical trial was performed using a standardised treatment group, in which poultry flocks were vaccinated at least twice with a selected H5N1 vaccine, and a control group comprising flocks treated with non-standardised procedures chosen by the farmer. Each group consisted of six flocks comprising either layers or native chickens. Haemagglutination inhibition (HI) antibody levels were determined by regular serum sampling, and outbreak surveillance relied on non-AI-vaccinated sentinel birds. After three vaccinations high antibody titres were produced in the treatment group, and the percentage of layers with an HI titre > 40 was approximately 90%. Although no conclusions can be drawn regarding reduction of virus transmission, this study demonstrated that 11 farms remained free from AI during the observation period, and that a surveillance programme based on differentiating infected from vaccinated animals (DIVA) can be implemented.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19284033     DOI: 10.20506/rst.27.3.1823

Source DB:  PubMed          Journal:  Rev Sci Tech        ISSN: 0253-1933            Impact factor:   1.181


  7 in total

Review 1.  Success factors for avian influenza vaccine use in poultry and potential impact at the wild bird-agricultural interface.

Authors:  David E Swayne; Erica Spackman; Mary Pantin-Jackwood
Journal:  Ecohealth       Date:  2013-09-12       Impact factor: 3.184

2.  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia.

Authors:  David E Swayne; David L Suarez; Erica Spackman; Samadhan Jadhao; Gwenaelle Dauphin; Mia Kim-Torchetti; James McGrane; John Weaver; Peter Daniels; Frank Wong; Paul Selleck; Agus Wiyono; Risa Indriani; Yuni Yupiana; Elly Sawitri Siregar; Teguh Prajitno; Derek Smith; Ron Fouchier
Journal:  J Virol       Date:  2015-01-21       Impact factor: 5.103

3.  Recombinant M2e protein-based ELISA: a novel and inexpensive approach for differentiating avian influenza infected chickens from vaccinated ones.

Authors:  Farhid Hemmatzadeh; Sumarningsih Sumarningsih; Simson Tarigan; Risa Indriani; N L P Indi Dharmayanti; Esmaeil Ebrahimie; Jagoda Igniatovic
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

4.  A single vaccination of commercial broilers does not reduce transmission of H5N1 highly pathogenic avian influenza.

Authors:  Okti Poetri; Annemarie Bouma; Ivo Claassen; Guus Koch; Retno Soejoedono; Arjan Stegeman; Michiel van Boven
Journal:  Vet Res       Date:  2011-06-02       Impact factor: 3.683

5.  Field effectiveness of highly pathogenic avian influenza H5N1 vaccination in commercial layers in Indonesia.

Authors:  Simson Tarigan; Michael Haryadi Wibowo; Risa Indriani; Sumarningsih Sumarningsih; Sidna Artanto; Syafrison Idris; Peter A Durr; Widya Asmara; Esmaeil Ebrahimie; Mark A Stevenson; Jagoda Ignjatovic
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

6.  Dose immunogenicity study of a plant-produced influenza virus-like particle vaccine in layer hens.

Authors:  Celia Abolnik; Tanja Smith; Daniel B R Wandrag; Mark-Anthony Murphy; Marizel Rautenbach; Olebile Olibile; Martha O'Kennedy
Journal:  Heliyon       Date:  2022-06-25

Review 7.  Pandemic potential of highly pathogenic avian influenza clade 2.3.4.4 A(H5) viruses.

Authors:  Reina Yamaji; Magdi D Saad; Charles T Davis; David E Swayne; Dayan Wang; Frank Y K Wong; John W McCauley; J S Malik Peiris; Richard J Webby; Ron A M Fouchier; Yoshihiro Kawaoka; Wenqing Zhang
Journal:  Rev Med Virol       Date:  2020-03-05       Impact factor: 11.043

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.